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 CURRENTOPINION Water and solute transport across the peritoneal
membrane
Johann Morellea,b and Olivier Devuyst a,b,c
Purpose of review
We review the molecular mechanisms of peritoneal transport and discuss how a better understanding of
these mechanisms is relevant for dialysis therapy.
Recent findings
Peritoneal dialysis involves diffusion and osmosis through the highly vascularized peritoneal membrane.
Computer simulations, expression studies and functional analyses in Aqp1 knockout mice demonstrated the
critical role of the water channel aquaporin-1 (AQP1) in water removal during peritoneal dialysis.
Pharmacologic regulation of AQP1, either through increased expression or gating, is associated with
increased water transport in rodent models of peritoneal dialysis. Water transport is impaired during acute
peritonitis, despite unchanged expression of AQP1, resulting from the increased microvascular area that
dissipates the osmotic gradient across the membrane. In long-term peritoneal dialysis patients, the fibrotic
interstitium also impairs water transport, resulting in ultrafiltration failure. Recent data suggest that stroke
and drug intoxications might benefit from peritoneal dialysis and could represent novel applications of
peritoneal transport in the future.
Summary
A better understanding of the regulation of osmotic water transport across the peritoneum offers novel
insights into the role of water channels in microvascular endothelia, the functional importance of structural
changes in the peritoneal interstitium and the transport of water and solutes across biological membranes
in general.
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INTRODUCTION
Adequate transport of water and small solutes is key
to successful peritoneal dialysis, a renal replacement
technique used by more than 200 000 patients with
end-stage renal disease worldwide [1]. As compared
with haemodialysis, peritoneal dialysis offers
increased flexibility and autonomy to patients,
along with similar outcomes [2]. Because of its
relative simplicity and lower cost, peritoneal dialysis
is rapidly growing in many parts of the world [1].
The principle of peritoneal dialysis is to use the
peritoneum as a dialysis membrane to continuously
draw waste products and excess fluids from the
patient’s blood towards the dialysate. Peritoneal
dialysis involves diffusive and convective trans-
ports, and osmosis through the highly vascularized
peritoneal membrane.
The peritoneum is a thin, translucent mem-
brane covering the inner surface of the abdominal
wall and the majority of the visceral organs. The
peritoneum can be viewed as a semi-permeable,
heteroporous membrane containing three major
components: a monolayer of mesothelial cells; an
interstitial tissue consisting of bundles of collagen in
a mucopolysaccharide hydrogel; and a dense net-
work of capillaries [3] (Fig. 1a). The endothelium
lining peritoneal capillaries and venules offers the
major rate-limiting hindrance for the transport of
water and solutes during peritoneal dialysis,
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restricting solute exchange to less than 0.1% of its
total surface area [4
&
]. Computer simulations
suggested the capillary endothelium to be function-
ally described by a three-pore model [5] (Fig. 1b).
This model postulated the existence of small pores
(radius, 40–50 A˚), located between endothelial cells,
accounting for nearly 99.5% of the total pore area
available for solute transport and contributing to
half the water removal (or ultrafiltration) through
solute-coupled water transport; large pores (radius,
250 A˚), responsible for the transcapillary transport
of macromolecules such as proteins and immuno-
globulins during peritoneal dialysis, representing
only 0.01% of the total number of pores; and ultra-
small pores (radius, <3 A˚), located in endothelial
cells, that would facilitate the transport of water
but not that of solutes (free-water transport).
Large epidemiological studies have evidenced
that parameters of peritoneal solute and water trans-
port are major determinants of outcome in perito-
neal dialysis patients [6–8]. Unravelling the
molecular mechanisms involved in these transport
processes is thus of utmost importance for patients
treated by peritoneal dialysis. The present review
summarizes current knowledge in this field of
research, focusing on recent insights obtained from
experimental models of peritoneal dialysis, and
from structural, molecular and functional analysis
of the human peritoneal membrane in cohorts of
peritoneal dialysis patients.
OSMOTIC WATER TRANSPORT AND ROLE
OF AQUAPORINS
From a physiological point of view, the phenom-
enon of osmosis occurs through a barrier restricting
the transport of solute compared with that of water.
For the peritoneal membrane, the existence of solute-
impermeable, ultrasmall pores in the capillary endo-
thelium has been postulated to explain the effective-
ness of glucose as an osmotic agent despite its small
size (3.7 A˚) and the phenomenon of sodium sieving.
Sodium sieving consists in the rapid fall in dialysate
sodium concentration during a dwell with hyper-
tonic glucose, and is predicted to result from free-
water transport across ultrasmall pores. These ultra-
small pores were predicted to have a major clinical
importance for peritoneal dialysis by mediating half
the ultrafiltration during a dwell with hypertonic
glucose [5,9].
In the early 1990s, aquaporin-1 (AQP1) was
identified as the archetypal member of a family of
membrane water channels, conserved in all living
organisms including plants [10–12]. The AQPs are
organized as homotetramers in plasma membranes,
with each monomer containing six tilted, mem-
brane-spanning a-helices surrounding a single cen-
tral pore. The selectivity of the pore for water
(against protons) is ensured by several elements,
including a narrow constriction of 2.8 A˚ [13], a
conserved arginine residue lining the pore and pro-
viding a fixed positive charge, a transient reorienta-
tion of the water dipole resulting from the
simultaneous formation of hydrogen bonding with
the side chains of two conserved asparagine residues
(NPA [Asn-Pro-Ala] motifs) and two partial positive
charges at the centre of the channel resulting from
two nonmembrane-spanning a helices [12]. AQP1
was initially discovered in red blood cells and in
renal proximal tubule cells [10,12,14], and is also
constitutively expressed in endothelial cells lining
peritoneal capillaries [14–16] (Fig. 2a,b).
Several lines of evidence demonstrated that
AQP1 constitutes the molecular counterpart of the
ultrasmall pore in the peritoneal membrane [4
&
].
Functional studies conducted in rats and rabbits
have shown that classical AQP antagonists such as
mercurial agents inhibit water transport across the
peritoneum [18,19]. The deletion of Aqp1 in mice
provided critical insights into the role of AQP1 in
water homeostasis. The Aqp1-knockout mice show a
severe defect in their urinary-concentrating ability
during water deprivation test (due to a defect in
KEY POINTS
 AQP1-mediated osmotic water transport significantly
contributes to water removal during peritoneal dialysis.
AqF026, the first identified AQP1 pharmacological
agonist, increases water removal in vivo, through
interaction with an intracellular gating domain.
 During acute peritonitis and long-term peritoneal
dialysis, an increase in the effective peritoneal surface
area, for instance due to local inflammation, leads to
faster absorption of glucose, early dissipation of the
osmotic gradient and loss of ultrafiltration.
 In long-term peritoneal dialysis patients, the fibrotic
interstitium reduces the osmotic conductance of the
peritoneal membrane, causing ultrafiltration failure. This
transport defect is predictive of encapsulating
peritoneal sclerosis.
 In a rat model of stroke, peritoneal dialysis efficiently
attenuates the transient increase in blood levels of
glutamate, thereby reducing propagation of ischemic
brain damage, infarct size and degree of disability.
 Liposome-supported peritoneal dialysis is a promising
approach to extract endogenous or exogenous
metabolites with a high efficiency, potentially relevant
for the treatment of metabolic disturbances and
drug intoxications.
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creating a hypertonic medullary interstitium by
countercurrent multiplication) [20], and a reduced
osmotic water transport across the peritoneal mem-
brane [21]. The development of mouse models of
peritoneal dialysis [22] as well as novel strategies to
accurately assess osmotic water transport in vivo [23
&
]
contributed to delineate the role of AQP1 water
channels during peritoneal dialysis. In these models,
the deletion ofAqp1 resulted in a nearly 70% decrease
in the initial, solute-free ultrafiltration rate, a nearly
50% decrease in cumulative ultrafiltration, and a
complete abolition of the sodium sieving, as com-
pared with their wild-type littermates [17,23
&
]
(Fig. 2c,d). Taken together, these studies inAqp1mice
validated two major predictions of the three-pore
model: ultrasmall pores mediate 50% of ultrafiltra-
tion during peritoneal dialysis with a hypertonic
glucose dialysate; and free-water transport accounts
for the observed sodium sieving [4
&
,5]. To date, AQP1
is the only identified molecular counterpart that is
directly involved in transport processes sustaining
peritoneal dialysis.
PERITONEAL SOLUTE TRANSPORT:
IMPACT OF LOCAL INTRAPERITONEAL
INFLAMMATION
Peritoneal transport of low molecular weight solutes
(such as urea and creatinine) occurs by diffusion
and convection through small pores, at the level
of inter-endothelial clefts, while transport of macro-
molecules is predicted to occur across large pores
[3,24]. The identity of these large pores has not been
established, even if some structures have been
postulated, including plasmalemma vesicles, vesicu-
lar-vacuolar organelles, large interendothelial clefts
or venular interendothelial gaps [3].
According to Fick’s principles, peritoneal solute
transport rate (PSTR) is primarily determined by the
number of perfused peritoneal capillaries in contact
with the dialysis solution (the effective peritoneal
surface area, EPSA), the intrinsic permeability of the
membrane and the concentration gradient between
blood and dialysate [3]. Data from large cohorts of
peritoneal dialysis patients with peritoneal equili-
bration testing at the initiation of peritoneal dialysis
indicate an important – more than two-fold – inter-
individual variability in the initial PSTR [25]. This
variability is clinically relevant, as faster solute
transport is associated with lower peritoneal ultra-
filtration capacity (due to early dissipation of the
osmotic gradient), and PSTR determines the perito-
neal dialysis prescription (dialysate dwell time, dex-
trose concentration, osmotic agent). Furthermore,
higher PSTR has been associated with a greater risk
of technique failure, and with an excessive risk of
death among patients on continuous ambulatory
peritoneal dialysis [7].
The effect of clinical variables (age, ethnicity,
comorbidity, level of serum albumin) on initial PSTR
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FIGURE 1. Structure of the peritoneal membrane and the three-pore model. (a) Cross-section of the human parietal peritoneum
stained for the von Willebrand factor (vWf). m, mesothelium; bar, 100 mm. (b) The three-pore model for peritoneal transport.
A˚, angstro¨m (1010 m); r, functional radius. Adapted with permission from [4&].
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is only about 30%, suggesting that additional factors
account for the inter-individual variability in PSTR
[26,27]. Interleukin (IL)-6, a cytokine mediating the
acute-phase inflammatory reaction able to increase
vascular permeability in vitro, is produced by meso-
thelial and resident cells in the peritoneal membrane
[28,29]. Concentrations of IL-6 in the dialysate -
taken as a surrogate for intraperitoneal inflammation
- have been associated with PSTR [29,30]. The Global
Fluid Study, a multinational, multicentre, prospec-
tive cohort, including almost 1000 peritoneal dialysis
patients, recently confirmed this association, by
showing that dialysate IL-6 level is the most import-
ant and independent determinant of PSTR in both
incident and prevalent peritoneal dialysis patients
[31]. Importantly, local intraperitoneal inflam-
mation does not affect patient survival, whereas
systemic inflammation – which is associated with
advanced age and comorbidity – has been shown to
be an independent predictor of death among patients
on peritoneal dialysis [31]. Altogether, these data
point towards local intraperitoneal inflammation
as the most important determinant of EPSA and
solute transport in peritoneal dialysis patients; as a
result, patients with an inflamed peritoneal mem-
brane are expected to have an enlarged EPSA, high
PSTR and increased protein loss in the peritoneal
effluent during peritoneal dialysis.
CHANGES IN PERITONEAL TRANSPORT
DURING ACUTE PERITONITIS
Acute peritonitis represents a severe complication
of peritoneal dialysis and is characterized by
recruitment and activation of leukocytes in the
peritoneal cavity, higher PSTR and protein loss in
the peritoneal effluent, leading to increased absorp-
tion of glucose, impaired ultrafiltration capacity and
fluid overload [15,32]. Vasoactive substances linked
to local inflammation, particularly nitric oxide, con-
tribute to these changes. Inhibition of nitric oxide
synthase (NOS) with NG-nitro-L-arginine methyl
ester was shown to improve ultrafiltration and to
reverse changes in PSTR in rat and mouse models of
acute peritonitis [33,34]. The use of acute peritonitis
models in mice lacking specific NOS isoforms –
neuronal NOS (nNOS), inducible NOS (iNOS) and
endothelial NOS (eNOS) – demonstrated the import-
ance of nitric oxide for structural and transport-
related alterations induced by acute peritoneal infec-
tion or inflammation. The deletion of eNOS, which
had no effect on peritoneal structure or transport
at baseline, significantly attenuated the vascular
proliferation and the inflammatory infiltrate in a
catheter-induced model of Gram-positive bacterial
peritonitis, resulting in improved ultrafiltration
[35]. Further investigations using a model of lipopo-
lysaccharide-induced peritonitis in mice deficient for
each NOSisoform confirmedthe specific roleofeNOS
in mediating increased solute transport and loss of
ultrafiltration associated with peritonitis, whereas
nNOS and iNOS have no effect [36]. In summary,
upregulation of eNOS and local nitric oxide pro-
duction increase vascular permeability and promote
angiogenesis and leukocyte adhesion, thereby con-
tributing to the functional changes in peritoneal
transport during acute peritonitis.
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FIGURE 2. Distribution and role of AQP1 in the peritoneal membrane. (a) Cross-section of the human parietal peritoneum
stained for AQP1. m, mesothelium; bar, 20mm. (b) Immunogold labelling of AQP1 on mouse visceral peritoneum. rbc, red
blood cells; bar, 500nm. (c and d) Effect of Aqp1 deletion on the transport of water across the peritoneal membrane. The
intraperitoneal volume versus time curves (IPVt) (c) and the initial ultrafiltration (UF) rates (d) are determined in Aqp1
þ/þ mice
(red symbols), Aqp1þ/ mice (blue symbols) and Aqp1/ mice (green symbols) during a 2-h exchange with hypertonic
dialysate. Adapted with permission from [4&,17].
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CHANGES IN PERITONEAL TRANSPORT
DURING LONG-TERM PERITONEAL
DIALYSIS
Prolonged exposure to nonphysiologic (acidic,
hyperosmolar, with high levels of glucose degra-
dation products) peritoneal dialysis solutions –
sometimes with repetitive episodes of peritonitis –
causes inflammation and damage to the peritoneal
membrane, which undergoes fibrosis, angiogenesis
and hyalinizing vasculopathy [37–40]. These
morphologic alterations have been associated with
increased PSTR and ultrafiltration failure [37–41],
thereby constituting an obstacle to long-term per-
itoneal dialysis, through an increased risk of tech-
nical failure, morbidity and mortality (for review,
see [39]).
Alternative models have been developed to inte-
grate the structural changes to predict peritoneal
transport modifications during long-term perito-
neal dialysis. The distributed model was developed
from a two-dimensional simulation that integrates
the microvasculature with the surrounding cells and
interstitium within the peritoneal membrane [42].
This model is particularly appropriate to analyse the
influence of parameters such as the local density of
blood vessels or the interstitium on the single endo-
thelial permeability [43]. A modified version of the
three-pore model included the capillary wall and a
serial barrier consisting of fibres in the interstitium
to predict more accurately long-term changes in
peritoneal transport related to alterations in the
microvasculature and interstitial compartment [44].
Predictions from the distributed and serial fibre
matrix/pore models were recently verified in a
cohort of long-term patients with severe peritoneal
remodelling, a feature of encapsulating peritoneal
sclerosis (EPS) [45
&
]. EPS constitutes the most severe
complication of peritoneal dialysis in which an
exaggerated fibrogenic response of the peritoneal
membrane (Fig. 3) leads to bowel encapsulation
and intestinal occlusion (for review, see [46]).
Patients who subsequently developed EPS showed
an early loss of ultrafiltration capacity and osmotic
conductance to glucose [45
&
,47,48], and this trans-
port defect was shown to be an independent and
powerful predictor of the risk of EPS [45
&
]. Recent
data indicate that reduced net ultrafiltration and
sodium sieving are directly related to the degree
of peritoneal fibrosis, and to collagen density and
the amount of thick collagen fibres in the sub-
mesothelial area, supporting the hypothesis that
the fibrotic interstitium restricts water transport
in vivo [45
&
] (Fig. 3). Importantly, the low osmotic
conductance and abolition of sodium sieving were
not associated with any change in AQP1 expression
or density in the peritoneal capillaries of these
patients [45
&
]. Accumulation of collagen fibres in
the interstitium – which normally constitutes a
porous matrix across which interstitial fluid flows
– has been suggested to decrease hydraulic conduc-
tance by at least three mechanisms: exclusion of
glycosaminoglycans from the intrafibrillar space,
thereby increasing their extrafibrillar concen-
tration; reduction of the mean hydraulic radius in
the interstitium, leading to a reduced area for flow;
and tortuosity, which increases the path length for
flow [49]. These data are in line with predictions
from the serial pore-membrane/fibre matrix and
distributed models that postulated that severe per-
itoneal fibrosis reduces osmotic conductance, either
through the development of a second – mechanical
– barrier outside the capillaries that restricts water
transport [44], or by reducing the penetration of the
osmotic agent in the peritoneal membrane, thereby
limiting the osmotic gradient across the capillary
wall [42,43]. Altogether, these data demonstrated
that the development of a fibrotic interstitium alters
osmotic water transport and provided a direct link
between severe peritoneal damage and altered func-
tional characteristics of the membrane.
TARGETED APPROACHES TO MODULATE
PERITONEAL TRANSPORT
Prevention and treatment of long-term peritoneal
dialysis-associated structural and functional
changes in the peritoneal membrane primarily rely
on the avoidance of peritoneal aggressions such as
peritonitis and chronic exposure to nonphysiolog-
ical peritoneal dialysis solutions. Interestingly, a
recent randomized controlled trial suggested that
the use of newer biocompatible peritoneal dialysis
solutions (reviewed in [50]) with neutral pH and low
levels of glucose degradation products could prevent
the increase in small solute transport that is associ-
ated with conventional peritoneal dialysis solu-
tions, during a 2-year follow-up [51].
More directly, the critical role of AQP1 in osmotic
water transport during peritoneal dialysis suggested
that water channels could be potential targets to
increase ultrafiltration and to restore fluid balance
in peritoneal dialysis patients [17]. The proof-of-
principle for that concept was provided by a study
in a rat model of peritoneal dialysis [52]. In this
model, high-dose dexamethasone increased AQP1
expression in peritoneal capillaries – through a glu-
cocorticoid element response in the promoter of the
Aqp1 gene – and enhanced free-water transport and
total ultrafiltration. Importantly, changes in water
transport occurred without any modification of
solute transport nor change in the osmotic gradient.
The effect of corticosteroids on AQP1 expression and
Molecular cell biology and physiology of solute transport
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FIGURE 3. Structural changes in the peritoneal interstitium reduce osmotic water transport in patients with encapsulating
peritoneal sclerosis (EPS). (a–d) Immunostaining for vWf in normal (a), uremic (b), control peritoneal dialysis (PD) (c) and EPS
(d) peritoneum. m, mesothelium; bar, 100mm. (e–h) Representative sections of peritoneum with evaluation of the degree of
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30mm. (i–l) Representative sections of parietal peritoneum from normal (i), uremic (j), control PD (k) and EPS (l) peritoneum
stained with picrosirius red. Bar, 100mm, mesothelium. (m,n) Correlation between net UF (m) or sodium sieving (n), and
submesothelial thickness in PD patients. Circles represent individuals; green circles for uremic, blue for PD and red for EPS
patients. Peritoneal transport parameters were obtained using a modified 4 h 3.86% glucose-based dialysate PET. (o) The
serial three-pore membrane/fiber matrix model, Adapted with permission from [44–45&].
Peritoneal water and solute transport Morelle and Devuyst
1062-4821 Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved. www.co-nephrolhypertens.com 439
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
water transport was recently confirmed in peritoneal
dialysis patients, by comparing data from functional
testing before and after living-donor kidney trans-
plantation. As compared with results from the pre-
transplantation period, peritoneal exchange tests
performed in three patients treated with high doses
of corticosteroids after kidney transplantation evi-
denced a two-fold increase in sodium sieving, paral-
leled by an increase in the ultrasmall pore-water
transport, although solute transport and small
pore-water transport remained unchanged [53].
In addition to molecules upregulating the
expression of water channels, the search for pharma-
cologic agonists of AQPs emerged as an exciting field
of investigation. Initial observations revealed that
plants counteract fluctuations in water supply
during drought stress or flooding through the gating
of their AQPs [54]. X-ray crystallography demon-
strated that the rapid gating of plant AQP results
from conformational changes of the intra-cyto-
plasmic loop D, which acts as a cap occluding or
opening the internal pore of water channels, in
response to de-phosphorylation of conserved serine
residues (drought stress), or to protonation of a
conserved histidine (flooding) [55]. This gating
mechanism appeared conserved throughout all
plant plasma membrane AQPs, and recent evidence
has suggested it also occurs in mammals. The bume-
tanide derivative AqB013 (Aq, aquaporin ligand; B,
bumetanide scaffold) blocks rat AQP1 and the
closely related AQP4 in vitro, by a mechanism
thought to involve physical occlusion of the intra-
cytoplasmic water channel pore [56]. By screening
a large library of arylsulfonamide compounds,
AqF026 (Aq, aquaporin ligand; F, furosemide scaf-
fold) was recently identified and characterized as the
first known AQP pharmacological agonist [57
&&
]
(Fig. 4a). In the Xenopus laevis oocyte system, extra-
cellularly applied AqF026 potentiated AQP1 (but
not AQP4)-mediated water transport by more than
20%. In-silico docking and site-directed mutagene-
sis in swelling assays demonstrated the critical role
of specific residues located in intra-cytoplasmic
loop D, involved in the gating of water channels
(Fig. 4b,c). In-vivo experiments using a mouse
model of peritoneal dialysis demonstrated that
AqF026 enhances AQP1-mediated water transport
and total ultrafiltration across the peritoneal mem-
brane (Fig. 4d,f), with no effect on osmotic gradient,
solute transport, expression levels of AQP1 and no
overt toxicity. The absence of potentiation effects in
Aqp1 knockout mice confirmed that AQP1 is the
specific target of AqF026. The development of
pharmacological modulators of AQP-mediated water
transport such as AqF026, which increases water
transport in vivo, offers perspectives for peritoneal
dialysis and clinical situations associated with disor-
dered fluid balance.
PERITONEAL DIALYSIS FOR NONRENAL
INDICATIONS
In addition to its role as renal replacement therapy,
an increasing body of evidence suggests that perito-
neal dialysis-induced osmosis can help treating fluid
overload in patients with refractory heart failure,
while improving functional status and quality of
life, and reducing morbidity and mortality of these
patients [58,59]. Furthermore, the capacity for dif-
fusive transport of glutamate and for trapping toxic
molecules into liposomes suggests that peritoneal
dialysis may also be useful for the treatment of
stroke and drug overdose, respectively.
Ischemic stroke results from a reduction in
cerebral blood flow restricted to the territory of a
major brain artery. The ischemic peri-infarct zone –
which is functionally impaired, still salvageable but
at risk for irreversible structural damage – is now
considered as a main target for therapy. In this peri-
infarct zone, glutamate, the most abundant neuro-
transmitter in mammals, was shown to play a
critical role in the propagation of ischemic brain
damage, by a mechanism called excito-toxicity. The
local release of glutamate after stroke also enhances
brain-to-blood efflux, leading to a transient increase
in its blood concentration, a finding that has been
associated with disease progression in patients with
acute ischemic stroke. In a rat model of stroke,
peritoneal dialysis was effective in attenuating the
transient increase in blood levels of glutamate after
stroke, thereby reducing excito-toxicity and propa-
gation of ischemic brain damage [60
&&
]. This effect
was associated with a reduced cerebral infarct size
measured 24 h after the arterial occlusion, as com-
pared with rats not treated with peritoneal dialysis.
Addition of glutamate to the dialysis solution com-
pletely abrogated the reduction in blood glutamate
levels and the beneficial effect of peritoneal dialysis
on infarct size, demonstrating the critical role of
glutamate clearance by diffusion across the perito-
neum. These acute benefits were reflected by a sig-
nificant improvement of tissue viability and
functionality, reducing the degree of disability [60
&&
].
The possibility to create nanosized liposomes
with a transmembrane pH gradient offers the possib-
ility to trap uncharged molecules (such as ammonia
or drug metabolites), which diffuse from the blood
into the acidic core of the liposome, become proto-
nated and then retained into the vesicle due to the
low diffusion of charged molecules across lipid
membranes. Recent data indicate that such lipo-
some-supported peritoneal dialysis (LSPD) is able
Molecular cell biology and physiology of solute transport
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to efficiently extract endogenous ammonia as well
as verapamil in rat models [61
&&
]. In-vivo exper-
iments showed that the acidic liposomes (initial
internal pH, 3.2) were able to extract endogenous
ammonia from the blood in a fast and efficient
manner (20-fold enrichment in peritoneal dialysis
fluid versus plasma after 3 h of LSPD). LSPD was also
tested in a rat model of verapamil intoxication, in
which the drug was removed from the circulation
much more effectively (30-fold increase) than with
peritoneal dialysis alone, resulting in a significant
decrease of the deleterious haemodynamic effects of
drug poisoning. Apart from verapamil, LSPD was
able to extract different basic and acidic drugs often
associated with intoxications, including proprano-
lol, amitriptyline, haloperidol, phenobarbital and
salbutamol. Furthermore, basic liposomes obtained
by using a calcium acetate buffer (internal pH, 10.0)
were shown to be able to extract propionic and
isovaleric acids in vitro, opening perspectives for
treatment of congenital metabolic disorders.
The relevance of these animal studies and the
possibility to add stroke and endogenous or
exogenous intoxications to the list of indications
for peritoneal dialysis need now to be rigorously
tested in patients.
CONCLUSION AND PERSPECTIVES
The AQP1 water channels play a critical role in water
removal during peritoneal dialysis, contributing to
the efficiency of the technique, and validating pre-
dictions from the three-pore model of the peritoneal
membrane. Modulating the expression or activity of
AQP1 enhances water transport, opening perspect-
ives to enhance ultrafiltration in peritoneal dialysis
patients. The transport of solutes across the perito-
neal membrane depends on the EPSA and is influ-
enced by peritoneal inflammation. In peritoneal
dialysis patients with acute peritonitis or on long-
term peritoneal dialysis, eNOS upregulation or vas-
cular proliferation increases EPSA, contributing to
faster solute transport, early dissipation of the
osmotic gradient and ultrafiltration failure. Long-
term peritoneal dialysis patients who develop an
exaggerated peritoneal fibrosis show a reduced
0
0
2.5
0.1
1.0
1.2
1.0
0.8
0.5
0.0
1.2
0 1.5 15
7.5 300.75
(d)
(a) (b) (c)
extracelluar
intracellular
C-terminusN-terminus
A C
1 2 3 4 5 6
E
B
D
(e) (f)
1 10
[AqF026] (µmol/l)
AqF026 concentration (µmol/l)
3.5
DMSO
AqF0264.5
30 60 90 120
10
In
it
ia
l U
F
 r
at
e 
(µ
/m
in
)
IP
V
t (
m
l)
R
el
at
iv
e 
in
cr
ea
se
 in
 n
et
 U
F
20
30
40
DMSO
Dwell time (min)
p = 0.016 between curves
Aqp1+/+Aqp1
+/+
Aqp1–/– Aqp1
–/– 
AqF026
O
O
O
S
Cl
O
O
NH
NH
FIGURE 4. AqF026, a novel agonist of AQP1, increases osmotic water transport in vivo. (a) Chemical structure of AqF026.
(b) In-silico modelling suggesting a direct interaction of AqF026 at a site located at the intracellular side of AQP1. (c)
Intracellular loop D domain (arrow), involved in the gating of AQPs, and critical for the effectiveness of AqF026. (d)
Significant, dose-dependent increase in net UF across the peritoneal membrane of wild-type Aqp1þ/þ mice treated with
AqF026. Data are meanSEM. (e) Increased intraperitoneal volume versus time (IPVt) among Aqp1þ/þ mice treated with
AqF026 (P¼0.016 between the AqF026 and vehicle curves). Blue triangles, AqF026-treated animals; open squares, vehicle-
treated animals. (f) Increased initial UF rates in Aqp1þ/þ mice treated with AqF026 (P<0.001 versus vehicle). AqF026 has
no effect on net UF and initial UF rates in Aqp1/ mice. DMSO, dimethyl sulfoxide. Data from [57&&].
Peritoneal water and solute transport Morelle and Devuyst
1062-4821 Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved. www.co-nephrolhypertens.com 441
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
osmotic conductance that is directly associated with
quantitative and qualitative changes in the fibrotic
interstitium, impeding osmotic water transport.
Recent developments suggest that the spectrum of
clinical applications of peritoneal transport might
extend beyond renal disease and include, in con-
ditions as stroke and intoxications.
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